The Medical Letter on Drugs and Therapeutics: Difference between revisions
Undid revision 409847093 by Saheinknab (talk) |
Undid revision 410770493 by 68.164.205.194 (talk) |
||
Line 11:
}}
The Medical Letter has a print plus electronic circulation of more than 450,000 subscribers in 125 countries worldwide. Published biweekly (
▲Published biweekly (26 issues/year), the newsletter is available in several languages: [[English language|English]] (US and Canadian editions), [[French language|French]] (Canadian and European editions), [[Italian language|Italian]], [[Japanese language|Japanese]], and [[Spanish language|Spanish]].The Medical Letter is also available as an electronic site license for institutions such as medical schools, hospitals and group practices.
== Editorial process ==
Articles for
== See also ==
| |||
Revision as of 15:35, 29 January 2011
| Discipline | Publication |
|---|---|
| Language | English, French, Italian, Japanese, Spanish and a Canadian adapted version, written in English |
| Publication details | |
| History | first published 1959 |
| Publisher | |
| Standard abbreviations | |
| ISO 4 | Med Lett Drugs Ther |
| Indexing | |
| ISSN | 1523-2859 |
| Links | |
The Medical Letter on Drugs and Therapeutics (usually referred to as The Medical Letter) is the non-profit publisher of The Medical Letter and Treatment Guidelines from The Medical Letter. Both publications offer health care professionals independent evaluations of therapeutic drugs. The Medical Letter is supported entirely by sales of its print and electronic publications. It does not accept advertisements, gifts, grants or donations, and does not accept bulk orders for reprints of its contents.
The Medical Letter has a print plus electronic circulation of more than 450,000 subscribers in 125 countries worldwide. Published biweekly (Treatment Guidelines is published monthly), it is available in several languages: English (US and Canadian editions), French (Canadian and European editions), Italian, Japanese, and Spanish.The Medical Letter is also available as an electronic site license for institutions such as medical schools, hospitals and group practices.
Editorial process
Articles for The Medical Letter are drafted by either an in-house editor or an outside consultant using both published and available unpublished studies that are reviewed for methodological rigor with special attention to the results of clinical trials. A preliminary draft is circulated to 10-20 medical investigators with relevant clinical or experimental experience. Drafts are also sent to the Food and Drug Administration (FDA) the first authors of all the articles cited in the text, to the pharmaceutical companies that make the drug(s) under review, and to the manufacturers of competing drugs. The evaluation of each drug includes a discussion of its effectiveness, side effects, and a comparison with other agents used for the same indication. The final version of the paper incorporates comments from the reviewers, and the final version is checked and edited for accuracy and readability.[1]
See also
References
- ^ "Flowchart of the editorial process" (pdf). The Medical Letter, Inc. Retrieved 2010-06-29.